New England Journal of Medicine – September 21, 2017  Vol. 377 No. 12

New England Journal of Medicine
September 21, 2017  Vol. 377 No. 12
http://www.nejm.org/toc/nejm/medical-journal

Perspective
Tuberculosis Elimination in the United States — The Need for Renewed Action
Bayer and K.G. Castro
Free Full Text

The Fate of FDA Postapproval Studies
Woloshin, L.M. Schwartz, B. White, and T.J. Moore
The Food and Drug Administration often requires postapproval studies to address issues such as optimal dosing, potential long-term side effects, and use in children or to confirm a drug’s clinical benefit. But many of these studies aren’t completed on time, if at all.